# Gland Pharma (NSE: GLAND) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GLAND · Pivot · prices to 22 Oct 2026

Gland Pharma (NSE: GLAND) closed at ₹2,910.60 on 22 Oct 2026, down 0.66% on the day. With a market capitalisation of ₹48,013 Cr, it ranks 198th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 46.7× trailing earnings, against a return on equity of 9.9% in FY26. Over the past year the share price has risen 52.0%. Its 52-week range is ₹1,573.60 (16 Mar 2026) to ₹3,171.00 (7 Oct 2026); the last close is 8.2% below the high. Promoters held 51.77% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹2,910.60 |
| Market cap | ₹48,013 Cr |
| P/E (trailing) | 46.7 |
| ROE | 9.9% (FY26) |
| ROCE | 14.0% (FY26) |
| Debt to equity | 0.02 |
| 52-week high | ₹3,171.00 (7 Oct 2026) |
| 52-week low | ₹1,573.60 (16 Mar 2026) |
| 1-year return | +52.0% |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹5,617 Cr | ₹699 Cr |
| FY24 | ₹5,665 Cr | ₹772 Cr |
| FY23 | ₹3,625 Cr | ₹781 Cr |
| FY22 | ₹4,401 Cr | ₹1,212 Cr |
| FY21 | ₹3,463 Cr | ₹997 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 51.77%
- Foreign institutions: 8.74%
- Domestic institutions: 30.44%
- Non-institutions: 9.05%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Aster DM Health](https://app.pivotnow.in/stock/ASTERDM) | ₹647.20 | ₹56,415 Cr | 101.1 | — |
| [Fortis Healthcare](https://app.pivotnow.in/stock/FORTIS) | ₹720.15 | ₹54,368 Cr | 52.3 | — |
| [Biocon](https://app.pivotnow.in/stock/BIOCON) | ₹332.85 | ₹54,244 Cr | 117.6 | — |
| [Abbott India](https://app.pivotnow.in/stock/ABBOTINDIA) | ₹25,445.00 | ₹54,069 Cr | 34.8 | — |
| [IPCA Laboratories](https://app.pivotnow.in/stock/IPCALAB) | ₹1,932.90 | ₹49,038 Cr | 43 | — |
| [Anthem Biosciences](https://app.pivotnow.in/stock/ANTHEM) | ₹802.40 | ₹45,206 Cr | 76.6 | — |

## Questions and answers

### What is the share price of Gland Pharma today?

Gland Pharma (NSE: GLAND) last closed at ₹2,910.60 on 22 Oct 2026. Its 52-week high is ₹3,171.00 and its 52-week low is ₹1,573.60.

### What is the market cap of Gland Pharma?

Gland Pharma's market capitalisation is ₹48,013 Cr (₹48,013 Cr) at the 22 Oct 2026 close, ranking 198th among the NSE companies Pivot tracks.

### What is the P/E ratio of Gland Pharma?

Gland Pharma trades at a trailing P/E of 46.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 76.6.

### What is the ROE and ROCE of Gland Pharma?

Return on equity was 9.9% in FY26 and return on capital employed was 14.0% in FY26 (consolidated figures).

### Is Gland Pharma a debt-free company?

Gland Pharma is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.

### How has Gland Pharma stock performed over the last year?

Gland Pharma's share price has risen 52.0% over the past year, +20.3% over three months and −0.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Gland Pharma?

As of 30 Jun 2026: promoters 51.77%, foreign institutions 8.74%, domestic institutions 30.44%, non-institutions 9.05%.

### Who are Gland Pharma's competitors?

The listed Pharma & Healthcare companies closest to Gland Pharma by market cap are Aster DM Health, Fortis Healthcare, Biocon, Abbott India, IPCA Laboratories and Anthem Biosciences.

### Is Gland Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Gland Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GLAND against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.